큐라클

365270KOSDAQ

48.1 / 100

Reference Date: 2026-09-08

Financial Score12.0 / 40

News Sentiment19.1 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Curacle is a biotech venture company developing innovative therapeutics targeting endothelial dysfunction, leveraging its proprietary platforms Solvadys and Eagles to advance first-in-class drug candidates such as CU06, CU71, and CU01. CU06, a retinal disease treatment, demonstrated vision improvement in Phase 2a trials, while collaborations with MapTics have expanded its antibody-based pipeline.

Number of Employees

31people

Average Salary

81.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

5.92Industry Average 1.200.0Point

4.9x industry avg (risky)

ROE

-54.03Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

9.08Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼25.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -40.6% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Neutral
“내 고양이 30살까지 산다고?”…화제의 日 신약 알고 보니
Positive
큐라클, 스탠다임과 특발성 폐섬유증 치료제 ‘CU72’ 개발
큐라클의 특발성 폐섬유증 치료제 'CU72' 개발 프로젝트가 정부 지원 사업에 선정되어 긍정적인 투자 전망을 제공합니다.
Positive
큐라클, 2·4분기 매출 72억·영업익 24억...기술이전 수익 반영
큐라클의 기술이전 수익과 매출 증가로 인해 2·4분기 실적이 개선되어 긍정적인 시장 반응을 보임.

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 9,910Won52-week high 19,71052-week low 4,565

1-month return3.0Point

1m 0.1% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14